The Central Drugs Standard Control Organisation (CDSCO) has unveiled alarming findings from its latest quality control report, revealing that 49 pharmaceutical products have failed to meet safety and efficacy standards. This extensive assessment, part of a routine surveillance effort, involved sampling nearly 3,000 drug batches across India in September alone. The implications for public health are significant, as many of these medications are commonly prescribed antibiotics, pain relievers, and supplements.
Overview of Quality Failures
The CDSCO's report highlighted that a number of widely used medications have been labeled as Not of Standard Quality (NSQ). Notable inclusions are:
- Metronidazole tablets by Hindustan Antibiotics
- Domperidone tablets by Rainbow Life Sciences
- Oxytocin injections by Pushkar Pharma
- Metformin tablets from Swiss Biotech Parentarels
- Calcium 500 mg with Vitamin D3 tablets by Life Max Cancer Laboratories
- PAN 40 by Alkem Labs
This revelation raises serious concerns about the efficacy of medications that patients rely on daily, particularly the widely used Paracetamol tablets produced by Karnataka Antibiotics & Pharmaceuticals Ltd.
Incidence of Substandard Medications
The report indicates a failure rate of approximately 1.5%, with 49 drugs recalled due to subpar quality. CDSCO's sampling and testing processes are critical in maintaining public health standards, as these checks help identify and remove ineffective drugs from the market.
Spurious Products Identified
In addition to the NSQ products, the CDSCO has flagged four medications as “spurious.” These include:
- Shelcal 500 (calcium supplement)
- Pan D (antacid)
- Urimax-D (used for enlarged prostate)
- Deca-Durabolin 25 injection (prescribed for osteoporosis)
These products are labeled as counterfeit due to the manufacturers' denial of involvement in their production. CDSCO has made it clear that further investigations are underway to ascertain the legitimacy of these products.
Ongoing Efforts in Drug Safety Surveillance
The CDSCO's commitment to drug safety is evident through its systematic approach to sampling and testing. Each month, the organization conducts rigorous quality checks to minimize the presence of NSQ drugs in the market. The results of these evaluations are made public on the CDSCO portal, enhancing transparency and keeping stakeholders informed about potential risks.
Dr. Rajeev Singh Raghuvanshi, the CDSCO Chief, emphasized the importance of vigilant monitoring, stating, “Vigilant action and monitoring of drugs by CDSCO drastically bring down the percentage of less efficacious drugs.” This proactive stance demonstrates the regulatory body’s dedication to safeguarding public health.
Recent Findings and Their Implications
The findings from the latest report are not isolated incidents; in recent months, CDSCO has flagged over 50 drugs for failing quality assessments, including medications for diabetes, hypertension, and common infections. Specific products previously identified include:
- Nimesulide and Paracetamol tablets by Innova Captab Limited
- Pantoprazole Gastro-resistant tablets by Alkem Health
- Cefpodoxime tablets by Aristo Pharmaceuticals
- Amoxicillin and Potassium Clavulanate tablets by Alkem Health
These repeated quality failures underscore the necessity for ongoing scrutiny within the pharmaceutical sector.
Read More: Maharashtra Assembly Polls: Congress Unveils Second List of 23 Candidates- Click Here
Conclusion
As the CDSCO continues its monthly surveillance, the goal remains clear: to protect public health by ensuring that only high-quality, effective medications are available in the market. The identification and recall of NSQ drugs are vital steps in maintaining the integrity of the pharmaceutical industry in India.
Consumers should remain vigilant and informed about the medications they use. If you’re taking any of the products mentioned in this report, consult your healthcare provider to ensure that your medications are safe and effective. The ongoing efforts by the CDSCO reflect a commitment to transparency and safety, ultimately fostering greater trust in the healthcare system.
